Showing 1-10 of 14 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Evaluation of a novel insulin sensitizer on glycemic control, insulin usage, and cardiovascular biomarkers in people with type 1 diabetes who use closed-loop automated insulin delivery | Rector & Visitors of the University of Virginia | William Horton | Improving Lives | 01-August-2025 to 31-July-2028 | $1,031,908.99 |
| Reducing Glycemic Variability to Improve Cardiovascular Health in Type 1 Diabetes | Rector & Visitors of the University of Virginia | William Horton | Improving Lives | 01-December-2022 to 30-June-2027 | $858,072.00 |
| Alternative Splicing as a Trigger for Initiation and Progression of Islet Autoimmunity | Rector & Visitors of the University of Virginia | Stephen Rich | Cures | 01-February-2026 to 31-January-2029 | $880,914.00 |
| Improving Genetic Risk Scores for Type 1 Diabetes in East Asian Populations | Rector & Visitors of the University of Virginia | Stephen Rich | Cures | 01-June-2026 to 31-May-2029 | $899,995.00 |
| ST2 Tregs in enhancing islet transplantation | Rector & Visitors of the University of Virginia | Rahul Sharma | Cures | 01-July-2025 to 30-June-2028 | $499,997.13 |
| Polyclonal IgM and Its Fcµ Fragment: Preclinical Advances Toward Type 1 Diabetes Therapy | Rector & Visitors of the University of Virginia | Preeti Chhabra | Cures | 01-May-2026 to 30-April-2029 | $982,880.00 |
| S1P transport inhibitors for prevention of T1D | Rector & Visitors of the University of Virginia | Kevin Lynch | Cures | 01-October-2024 to 30-September-2026 | $520,627.00 |
| Anti-CD71 immunotherapy to restore T cell homeostasis in autoimmunity | Rector & Visitors of the University of Virginia | Kelsey Voss | Cures | 01-September-2025 to 31-December-2026 | $150,000.00 |
| Development of simulation tools to support adaptation of automated insulin delivery algorithms across pregnancies complicated by type 1 diabetes | Rector & Visitors of the University of Virginia | Jacopo Pavan | Improving Lives | 01-March-2025 to 28-February-2027 | $189,316.00 |
| Dual Beta-cell Regenerative and Immunomodulatory Endogenous Agonist as a Replacement Therapy for Type 1 Diabetes | Rector & Visitors of the University of Virginia | Gordon Laurie | Cures | 01-October-2025 to 30-September-2027 | $300,000.00 |